Late complications of therapy of Hodgkin's disease: prevention and management - PubMed (original) (raw)
Affiliations
- PMID: 14695846
Review
Late complications of therapy of Hodgkin's disease: prevention and management
Andrea K Ng et al. Curr Hematol Rep. 2004 Jan.
Abstract
Patients diagnosed with Hodgkin's disease have a high cure rate. However, long-term survivors of the disease are at significantly increased risk for many late complications. The most serious late effects faced by these patients include the development of a second malignancy or cardiovascular disease. Ongoing trials investigating treatment reduction, including using lower radiation dose, smaller radiation field size, and abbreviated chemotherapy, will hopefully help in limiting the treatment-related complications. Continued long-term follow-up of survivors, careful documentation of the broad range of late effects, identification of risk factors, development and evaluation of screening programs, and preventative therapy for specific late complications are important steps in improving the survival and quality of life of patients who have been cured of Hodgkin's disease.
Similar articles
- Late effects of Hodgkin's disease and its treatment.
Ng AK, Mauch PM. Ng AK, et al. Cancer J. 2009 Mar-Apr;15(2):164-8. doi: 10.1097/PPO.0b013e31819e30d7. Cancer J. 2009. PMID: 19390314 Review. - Are we improving the long-term burden of Hodgkin's lymphoma patients with modern treatment?
Aleman BM, van Leeuwen FE. Aleman BM, et al. Hematol Oncol Clin North Am. 2007 Oct;21(5):961-75. doi: 10.1016/j.hoc.2007.07.005. Hematol Oncol Clin North Am. 2007. PMID: 17908631 Review. - Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up.
Brusamolino E, Baio A, Orlandi E, Arcaini L, Passamonti F, Griva V, Casagrande W, Pascutto C, Franchini P, Lazzarino M. Brusamolino E, et al. Clin Cancer Res. 2006 Nov 1;12(21):6487-93. doi: 10.1158/1078-0432.CCR-06-1420. Clin Cancer Res. 2006. PMID: 17085663 - Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications.
Koontz BF, Kirkpatrick JP, Clough RW, Prosnitz RG, Gockerman JP, Moore JO, Prosnitz LR. Koontz BF, et al. J Clin Oncol. 2006 Feb 1;24(4):605-11. doi: 10.1200/JCO.2005.02.9850. J Clin Oncol. 2006. PMID: 16446333 - Nonmalignant complications of therapy for Hodgkin's disease.
Hohl RJ, Schilsky RL. Hohl RJ, et al. Hematol Oncol Clin North Am. 1989 Jun;3(2):331-43. Hematol Oncol Clin North Am. 1989. PMID: 2663831 Review.
Cited by
- Disparities in survival after Hodgkin lymphoma: a population-based study.
Keegan TH, Clarke CA, Chang ET, Shema SJ, Glaser SL. Keegan TH, et al. Cancer Causes Control. 2009 Dec;20(10):1881-92. doi: 10.1007/s10552-009-9382-3. Cancer Causes Control. 2009. PMID: 19557531 Free PMC article. - Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.
Franklin J, Eichenauer DA, Becker I, Monsef I, Engert A. Franklin J, et al. Cochrane Database Syst Rev. 2017 Sep 13;9(9):CD008814. doi: 10.1002/14651858.CD008814.pub2. Cochrane Database Syst Rev. 2017. PMID: 28901021 Free PMC article. Review. - Young Adult Cancer Survivorship: Recommendations for Patient Follow-up, Exercise Therapy, and Research.
Adams SC, Herman J, Lega IC, Mitchell L, Hodgson D, Edelstein K, Travis LB, Sabiston CM, Thavendiranathan P, Gupta AA. Adams SC, et al. JNCI Cancer Spectr. 2020 Oct 28;5(1):pkaa099. doi: 10.1093/jncics/pkaa099. eCollection 2021 Feb. JNCI Cancer Spectr. 2020. PMID: 33681702 Free PMC article. Review. - Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk.
Franklin JG, Paus MD, Pluetschow A, Specht L. Franklin JG, et al. Cochrane Database Syst Rev. 2005 Oct 19;2005(4):CD003187. doi: 10.1002/14651858.CD003187.pub2. Cochrane Database Syst Rev. 2005. PMID: 16235316 Free PMC article. Review. - Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE, Zhang L, Heslop HE, Brenner MK, Dotti G. Savoldo B, et al. Blood. 2007 Oct 1;110(7):2620-30. doi: 10.1182/blood-2006-11-059139. Epub 2007 May 16. Blood. 2007. PMID: 17507664 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical